Dogwood Therapeutics shareholders approve warrant exercise for up to 4.4M shares

Dogwood Therapeutics, Inc.

Proposal to approve potential exercise of warrant for 4,386,037 shares passed with 29,286,786 votes for, 19,057 against, 4,466 abstentions.
Approval required under Securities Purchase Agreement dated Jan 11, 2026 and Nasdaq Listing Rule 5635(d).
Adjournment proposal also approved with 29,283,790 for, 21,571 against.
Quorum of 29,310,309 shares (88.03% of voting power) present at Special Meeting held March 11, 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.